Skip to main content

Table 2 Clinical characteristics and lung function parameters in different treatment groups

From: Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations. A real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation

  BDP/F extrafine pMDI (n = 53) BUD/F and FP/S DPI (n = 58)
Male, n (%) 15 (28.3%) 15(25.8%)
Age, years (mean and range) 48 (19-84) 47 (18-86)
Current smokers, n (%) 20 (37.7%) 19 (32.8%)
Allergies, n (%) 40 (75.5%) 41 (70.6%)
Patients using SABA for as needed medication, n (%) 53 (100%) 50 (86.2%)
Patients using BUD/F for as needed medication, n (%) 0 (0%) 8 (13.8%)
Initial diagnosis of mild persistent asthma, n (%) 0 (0%) 0 (0%)
Initial diagnosis of moderate persistent asthma, n (%) 45 (84.9%) 49 (84.5%)
Initial diagnosis of severe persistent asthma, n (%) 8 (15.1%) 9 (15.5%)
FEV1(mean ± SE; % of predicted) 81.71 ± 17.53 79.38 ± 17.71
PEF (mean ± SE; % of predicted) 78.47 ± 19.92 75.34 ± 22.12
FEF 25-75 (mean ± SE; % of predicted) 62.35 ± 26.18 56.52 ± 23.3
MEF 75 (mean ± SE; % of predicted) 71.53 ± 28.38 71.41 ± 29.01
MEF 25 (mean ± SE; % of predicted) 58.2 ± 26.12 53.74 ± 24.23
  1. SABA = short acting beta2-agonist; BDP = beclomethasone dipropionate; BUD = budesonide; FP = fluticasone propionate; F = formoterol; S = salmeterol. #In pMDI group spirometry data were not available in 2 patients.